Thrilled to share that our preprint is now published in Cancer Research Communications! Key insights from our publication: -LNS8801 is the active component in the “selective GPER agonist” known as G-1 -LNS8801 is orally bioavailable and effective at low doses/exposures. -Efficacious in murine and human models of cancer, in vivo. -GPER is essential for LNS8801's activity, validated in 3 independent systems. -GPER expression in tumors is required for in vivo activity -A hypofunctional germline GPER variation attenuates GPER activation by LNS8801. This manuscript underscores the therapeutic potential of LNS8801 and targeting GPER in cancer treatment. LNS8801 is now advancing through clinical trials!
Linnaeus Therapeutics, Inc.
生物技术研究
Haddonfield，New Jersey 616 位关注者
Privately held biotech developing drugs for cancer
关于我们
Linnaeus Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics that target G protein-coupled receptors. The company was formed and launched in partnership with the UPstart incubator at the University of Pennsylvania’s Penn Center for Innovation (PCI).
- 网站
-
https://linnaeustx.com/
Linnaeus Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Haddonfield，New Jersey
- 类型
- 私人持股
- 创立
- 2016
- 领域
- Cancer Therapy
地点
-
主要
获取路线
30 Washington Ave
Suite F
US，New Jersey，Haddonfield，08033